Live news related to OSE IMMUNO stock (FR0012127173): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
OSE Immunotherapeutics announces that its partner Veloxis Pharmaceuticals has received orphan drug designation from the FDA for pegrizeprument (VEL-10…
OSE Immunotherapeutics announces the selection of its Phase 2 TEDOVA clinical trial results for an oral presentation at the 2026 American Society of C…
OSE Immunotherapeutics announces the presentation of a new FPR2 agonist monoclonal antibody, described as first-in-class, at the 2026 American Associa…
OSE Immunotherapeutics announces the appointment of Thomas Gidoin as Deputy CEO and Aurore Morello as Chief Scientific Officer. These changes in its l…
OSE Immunotherapeutics announces its participation in two investor conferences scheduled for spring 2026. The management will present the company and …
OSE Immunotherapeutics announces the permanent appointment of Marc Le Bozec as CEO, effective immediately. Mr. Le Bozec has been serving in this role …
OSE Immunotherapeutics announces the receipt of a second positive opinion from the Independent Data Monitoring Committee (IDMC) for its pivotal Phase …
OSE Immunotherapeutics announces the selection of two new clinical indications for lusvertikimab (OSE-127): chronic pouchitis and hidradenitis suppura…
The FDA has granted orphan drug designation to pegrizeprument (VEL-101) for the prevention of organ rejection in patients undergoing liver transplanta…
OSE Immunotherapeutics has revealed its strategic plan for the period 2026 - 2028, focusing on four value creation levers, with an emphasis on the dev…
